regulatoryhigh confidence

FDA Approves Talazoparib Plus Enzalutamide for Metastatic Prostate Cancer With HRR Gene Mutations

|Cancer Breakthroughs

The FDA listed approval on October 26, 2026 of talazoparib (Talzenna) with enzalutamide for metastatic androgen-pathway-modulation-naive or sensitive prostate cancer with homologous recombination repair gene mutations. Efficacy figures were not read from the notification.

Media

FDA oncology approval notification
FDA oncology approval notification — U.S. FDA

Sources

View full Cancer Breakthroughs dashboard